Literature DB >> 28359247

Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.

Liang Zhao1, Jessie L-S Au1, M Guillaume Wientjes2.   

Abstract

BACKGROUND: Commonly used methods for analyzing interactivity between drugs (e.g. synergy, antagonism) such as isobologram, combination index, and curve shift are based on the Loewe Additivity principle of dose equivalence and the inherent assumption of similar concentration- effect (C-E) including parallel curves and equal maximum effects (Emax), and therefore are not suitable for drugs with dissimilar C-E. This study describes a new method that is without this limitation and has the additional advantage of enabling statistical analysis. METHODS AND
RESULTS: The method comprises two steps. First, based on the dose equivalence principle, the experimentally obtained C-E of one drug was used to calculate the equally effective C-E of the other drug at no interactivity; the resulting two zero-interactivity C-E formed the upper and lower boundaries of Additivity Envelope. Next, 95% confidence intervals calculated from experimental data were added to Additivity Envelope to obtain Uncertainty Envelope (UE). Experimentally observed effects of drug combinations (C-Ecomb,observed) located within UE indicate additivity whereas C-Ecomb,observed located above or below UE indicate statistically significant (p<0.05) synergy or antagonism, respectively. Additional in silico studies demonstrated the shape and size of Additivity Envelope, which determines the ability to detect drug interactivity, depended on the Drug A-to-B concentration ratios and the ratios of their C-E curve shape parameter. Analyses of experimental results of combinations of drugs with nonparallel C-E and/or unequal Emax indicated UE as more versatile and provided more information, compared to earlier methods.
CONCLUSION: UE is a broadly applicable method for analysis, including statistical significance assessment, of drug interactivity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Combination therapy; antagonism; drug-drug interactivity; loewe-additivity; statistically significant synergy; uncertainty envelope

Mesh:

Substances:

Year:  2017        PMID: 28359247      PMCID: PMC5623138          DOI: 10.2174/1568009617666170330154054

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  30 in total

1.  Isobolographic analysis for combinations of a full and partial agonist: curved isoboles.

Authors:  Yury Grabovsky; Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2004-06-02       Impact factor: 4.030

Review 2.  The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.

Authors:  Ronald J Tallarida; Robert B Raffa
Journal:  Pharmacol Ther       Date:  2010-05-28       Impact factor: 12.310

Review 3.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

6.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

7.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

8.  Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

Authors:  W R Greco; H S Park; Y M Rustum
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

9.  A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.

Authors:  Boleslav Kosharskyy; Nicolas Solban; Sung K Chang; Imran Rizvi; Yuchiao Chang; Tayyaba Hasan
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

10.  Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.

Authors:  Kongfei Li; Chao Hu; Chen Mei; Zhigang Ren; Juan Carlos Vera; Zhengping Zhuang; Jie Jin; Hongyan Tong
Journal:  J Transl Med       Date:  2014-06-12       Impact factor: 5.531

View more
  2 in total

Review 1.  Pharmacodynamic Drug-Drug Interactions.

Authors:  Jin Niu; Robert M Straubinger; Donald E Mager
Journal:  Clin Pharmacol Ther       Date:  2019-04-26       Impact factor: 6.875

2.  A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy.

Authors:  Jin Wang; Bertrand Z Yeung; M Guillaume Wientjes; Minjian Cui; Cody J Peer; Ze Lu; William D Figg; Sukyung Woo; Jessie L-S Au
Journal:  Pharmaceutics       Date:  2021-06-30       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.